A brief look at Incanthera

Incanthera has broken a clinical barrier in skincare. Its range is about to enter the real world. Incanthera (AQSE: INC) shares are currently changing hands for 15p apiece, more than doubling since the start of the year. This is a growth stock which has been on my radar for a while, ever since the market […]
medical leap

Every medical leap forward is really just one of many small steps

From cystic fibrosis to diabetes to strep — every medical find requires refinement and improvement over time. There is a video floating around out there, of an ex Royal Marine being treated for previously untreatable Parkinson’s Disease. I also quite like the ones of deaf people getting cochlear implants switched on for the first time. […]

What lessons can be learned from Avacta’s placing?

Avacta retains a significant set of oncology assets. But this, by itself, is not enough to be successful in the biotech space. Before we get started, I want to make clear that this is not an article designed to rub salt in the wound. If you are feeling betrayed, hurt, financially violated, or otherwise — […]

2024 small cap London biotechs to watch

Avacta, Hemogenyx, Cizzle and Poolbeg Pharma remain my top four biotech picks for 2024. Here’s why. There are many, many biotechs out there. Most are funding trials into a single flagship treatment — with a standard Chance of Success of circa 10%. However, when research houses talk about a 10% CoS, this concerns scientific success […]

Hemogenyx shares: where next?

HEMO’s investment case is much strengthened since January, though the immediate cash issues remain a concern. my thoughts below. Hemogenyx. It’s been a while since I covered this oncology portfolio stock — last running through the investment case in late January 2023. I’d encourage would-be investors who are new to the company to briefly scan […]
Oxford Biodynamics shares

Oxford Biodynamics shares: another oncology biotech for the portfolio

Oxford Biodynamics shares have shot up, and deservedly so. However, there will likely be a pullback for a better entry point. Oxford Biodynamics (LON: OBD) shares were changing hands for as much as 278p five years ago and had collapsed to circa 10.5p towards the end of September 2023. The share has now shot up […]
Cizzle Biotech

Cizzle shares: breaking down interim results

Cizzle shares now look decent value for long-term investors — a strong component for the biotech portfolio. Read the condensed update below. With a slew of AIM companies reporting results — I thought it would be a good idea to take a brief look at Cizzle for the first time since late February. Alongside Avacta […]

Investing Strategy: The Avacta Edit

Key things you need to know about investing in small cap oncology research stocks — including the best biotech on the AIM market. As a freelance financial analyst, I spend most of my time evaluating EIS-qualifying companies for high net worth investors, alongside coverage of market titans for blue chip clients. Much of this material […]

How to invest in junior biotech shares: 4 best platforms in 2023

As with every article featured here, none of this is investing or financial advice. We encourage you to conduct your own research. Here at Investing Strategy, we like to cover high-risk, high-reward shares in select sectors which provide the best opportunities in relatively short time frames. One of these sectors is biotechs (or life sciences) […]
Abingdon Health

Abingdon Health shares: another biotech stock to watch

ABDX is shortly launching a world-first saliva pregnancy test. It could become the global standard. Abingdon Health (LON: ABDX) shares have shot up by over 100% year-to-date as investors in the FTSE AIM biotech are finally starting to see some light at the end of the tunnel. The company put to bed a hotly contested […]